Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Videx Use With Zerit May Increase Pancreatitis Risk, Bristol Warns

Executive Summary

The majority of pancreatitis deaths in Videx-treated patients reported to FDA's MedWatch program have been in patients also on Bristol-Myers Squibb's other nucleoside, Zerit (stavudine, d4T), a Bristol "Dear Doctor" letter reports.

You may also be interested in...



Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results

Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS035250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel